Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 10
Barriers to Implementing ctDNA Testing
Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges.
- What are some barriers that have been observed to implementing routine standard-of-care ctDNA testing?
- Do barriers differ between academic and community settings?
- Do you have any practical tips to navigate these barriers to implementation?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
